Financials data is unavailable for this security.
View more
Year on year Cardiff Oncology Inc had net income fall 7.07% from a loss of 38.70m to a larger loss of 41.44m despite a 26.42% increase in revenues from 386.00k to 488.00k.
| Gross margin | -- |
|---|---|
| Net profit margin | -6,143.91% |
| Operating margin | -6,711.28% |
| Return on assets | -49.98% |
|---|---|
| Return on equity | -58.84% |
| Return on investment | -57.60% |
More ▼
Cash flow in USDView more
In 2023, Cardiff Oncology Inc increased its cash reserves by 32.47%, or 5.31m. Cash Flow from Investing totalled 36.20m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 30.89m for operations while cash from financing was breakeven.
| Cash flow per share | -0.905 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1.15 |
|---|---|
| Tangible book value per share | 1.15 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.97 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
